


ANSWER 50 OF 89 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 03 May 1999
 GI



AB Compds. represented by general formula (I) or salts thereof, (wherein n is an integer of 2 or 3; R represents a straight-chain or branched saturated alkyl group having 4 or 5 carbon atoms, a cyclopentyl group, a cyclohexyl group or the like; Y represents a hydroxyl or amino group; A represents a hydrogen atom, a hydroxyl, methoxy, nitro group or the like; Q represents a hydrogen atom or a hydroxyl or methoxy group) are claimed and prepared. They can be formulated to give pharmaceutical compns. that are effective as prophylactic or therapeutic agents for allergic diseases associated with IgE (IgE) production inhibitors or IgE antibodies, e.g. bronchial asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis. Thus, Me 3-(2-hydroxy-1,1'-biphenyl-5-yl)propionate was alkylated by Bu iodide in the presence of K₂CO₃ in DMF at room temperature for 16 h followed by saponification

in a mixture of 2 N aqueous NaOH and MeOH and acidification to give 3-(2-butoxy-1,1'-biphenyl-5-yl)propionic acid (II). II p.o. in vivo inhibited 72.3% IgE production in mice sensitized by egg white albumin.

ACCESSION NUMBER: 1999:271327 HCAPLUS <<LOGINID::20070820>>
 DOCUMENT NUMBER: 130:281874
 TITLE: Preparation of biphenyl-5-alkanoic acid derivatives as IgE antibody production inhibitors
 INVENTOR(S): Shoda, Motoshi; Itoh, Hiromichi
 PATENT ASSIGNEE(S): Asahi Kasei Kogyo Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 128 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9919291	A1	19990422	WO 1998-JP4456	19981002
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2304713	A1	19990422	CA 1998-2304713	19981002
CA 2304713	C	20030610		
AU 9892824	A	19990503	AU 1998-92824	19981002
AU 735737	B2	20010712		
EP 1024130	A1	20000802	EP 1998-945584	19981002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1103332	B	20030319	CN 1998-810235	19981002
US 6376546	B1	20020423	US 2000-509683	20000608
PRIORITY APPLN. INFO.:			JP 1997-280814	A 19971014
			WO 1998-JP4456	W 19981002


OTHER SOURCE(S): MARPAT 130:281874

IT 222627-02-3P, 3-(2-(Carboxymethoxy)-1,1'-biphenyl-5-yl)propionic acid 222627-38-5P, 4-(2-(Carboxymethoxy)-1,1'-biphenyl-5-yl)butyric acid

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylalkanoic acid derivs. as IgE antibody production inhibitors for treatment and preparation of allergic diseases)


RN 222627-02-3 HCAPLUS

CN [1,1'-Biphenyl]-3-propanoic acid, 6-(carboxymethoxy)- (9CI) (CA INDEX NAME)



RN 222627-38-5 HCAPLUS

CN [1,1'-Biphenyl]-3-butanoic acid, 6-(carboxymethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT